Puma Biotechnology, Inc.
PBYI
$7.17
$0.091.27%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -40.61% | 38.51% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -40.61% | 38.51% | |||
| Cost of Revenue | -54.93% | 89.99% | |||
| Gross Profit | -34.28% | 23.70% | |||
| SG&A Expenses | 0.24% | 9.29% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -16.63% | 29.94% | |||
| Operating Income | -122.38% | 78.69% | |||
| Income Before Tax | -120.03% | 85.08% | |||
| Income Tax Expenses | -91.11% | 819.55% | |||
| Earnings from Continuing Operations | -127.93% | 51.94% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -127.93% | 51.94% | |||
| EBIT | -122.38% | 78.69% | |||
| EBITDA | -106.56% | 54.23% | |||
| EPS Basic | -127.65% | 51.91% | |||
| Normalized Basic EPS | -119.82% | 85.02% | |||
| EPS Diluted | -128.63% | 51.65% | |||
| Normalized Diluted EPS | -120.29% | 82.98% | |||
| Average Basic Shares Outstanding | 1.00% | 0.00% | |||
| Average Diluted Shares Outstanding | -1.31% | 1.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||